Not a supplement, drug, or food ingredient — a compound gut bacteria build from a dietary amino acid. In people it has almost always been measured, not given. Higher amounts track lower hand-joint pain and calmer bowels, but also worse heart, cancer-treatment and kidney findings. Animal and laboratory results far outrun the human record. (Full Review)

Protocol

Infant-type bifidobacteria route

8 × 10⁹ CFU daily

Bifidobacterium longum subsp. infantis; the colony-forming-unit dose used in the trials that raised fecal concentrations

Adult fermented-milk route

B. longum BB536 in fermented milk

Raised fecal concentrations in healthy adults within 17 days

Competing approach — prebiotic first

Fibre-led regimen

Raises production without introducing an organism, by lowering colonic pH and freeing tryptophan from competing indole producers

Time to effect

Days to weeks

Fecal concentrations rise on a producing organism; significant increases by day 17. No human clinical outcome has been measured, so no time-to-benefit figure exists

Exercise

Acute rise

A single session raised circulating concentration; ten weeks of multimodal functional training raised the metabolite-based neuroprotection index in a multiple sclerosis trial

Half-life

Not published in humans

In mice, oral doses hold steady concentrations over hours, consistent with daily rather than multiple-daily dosing

Benefits

Medium: Lower odds of symptomatic hand osteoarthritis; lower intestinal inflammation; skin barrier support and reduced skin inflammation

Low: Support for mood via the bacteria that produce it

Speculative: Suppression of colorectal tumour growth; reduced amyloid accumulation and cognitive protection; attenuated age-related inflammation and gut barrier decline; improved insulin sensitivity

Contraindications

Anyone receiving anti-PD-1 checkpoint immunotherapy

Chronic kidney disease stage 4 or 5 (estimated filtration below 30 mL/min/1.73 m²)

Anyone on dialysis

Pregnancy and breastfeeding

Preterm and term neonates outside a supervised trial

Central venous catheter, severe immunosuppression or short bowel syndrome

Key Interactions

Broad-spectrum antibiotics (amoxicillin-clavulanate, ciprofloxacin, clindamycin)

Proton pump inhibitors and antacids (omeprazole, esomeprazole, calcium carbonate)

Tryptophan and 5-HTP supplements

Statins (atorvastatin, rosuvastatin, simvastatin)

Probiotics carrying the producing enzyme (Bifidobacterium longum, Bifidobacterium breve, Lactiplantibacillus plantarum)

Prebiotic fibres (inulin, galacto-oligosaccharides, beta-glucan, resistant starch)

Fecal microbiota transplantation and exercise training

Risk & Side Effects

Medium: Higher circulating levels track cardiovascular events and death; reduced response to cancer immunotherapy; elevated newborn levels linked to later attention deficits

Low: Accumulation when kidney filtration falls

Speculative: Immune dampening from sustained receptor activation; central nervous system exposure and appetite effects; unknown consequences in pregnancy

Monitoring

Marker	Target	Why
Plasma indole-3-lactic acid	No established target; track change from own baseline	Direct measure of systemic exposure
Fecal indole-3-lactic acid	No established target; track change from own baseline	Reflects colonic production rather than systemic exposure
hs-CRP	Below 0.5 mg/L	Tracks the low-grade inflammation the compound is proposed to lower
eGFR (cystatin C based)	Above 90 mL/min/1.73 m²	Falling filtration raises blood concentrations independently of production
Fecal calprotectin	Below 50 µg/g	Objective marker of intestinal inflammation, the best-supported target
Stool Bifidobacterium relative abundance	No established adult target; track change from own baseline	Indicates whether the producing organisms are actually present
Serum tryptophan	45–75 µmol/L	Substrate availability for the whole pathway

Cadence: Kidney filtration and inflammation markers at 3 months, then every 6–12 months; the metabolite and stool composition at 3 months and again at 12 months

Qualitative Assessment

Stool form and frequency, which respond to fermentable fibre before any metabolite shift is detectable
Abdominal bloating and gas, which indicate whether fibre was introduced too quickly
Energy levels through the afternoon, a non-specific but sensitive marker of gut-related inflammation
Cognitive clarity and mood stability, the domains where the animal work is most active and human data most absent
Skin comfort and barrier behaviour, given that resident skin bacteria produce the same compound

Indole-3-Lactic Acid for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment